{"log_id": 7840832611796015387, "direction": 0, "words_result_num": 39, "words_result": [{"probability": {"variance": 0.000206, "average": 0.976916, "min": 0.961344}, "location": {"width": 78, "top": 80, "height": 26, "left": 1092}, "words": "国家食"}, {"probability": {"variance": 0, "average": 0.999899, "min": 0.999899}, "location": {"width": 50, "top": 120, "height": 27, "left": 1129}, "words": "药"}, {"probability": {"variance": 0, "average": 0.999979, "min": 0.999979}, "location": {"width": 29, "top": 162, "height": 27, "left": 1142}, "words": "附"}, {"probability": {"variance": 0.02463, "average": 0.909137, "min": 0.421599}, "location": {"width": 514, "top": 233, "height": 37, "left": 249}, "words": "生过量服药,瘦对性反应进行监测并进行必要的治疗"}, {"probability": {"variance": 0.011263, "average": 0.971702, "min": 0.382349}, "location": {"width": 801, "top": 273, "height": 42, "left": 291}, "words": "如果发生药物过;必须监测患者是否有中毒的证据,必要时采取标准的支持疗法可"}, {"probability": {"variance": 0.003009, "average": 0.964314, "min": 0.831482}, "location": {"width": 846, "top": 310, "height": 45, "left": 247}, "words": "以通过血液透析清除阿德福韦阿德福韦经体童校正后的血液透析清除率中位数为"}, {"probability": {"variance": 0.019167, "average": 0.937652, "min": 0.462919}, "location": {"width": 486, "top": 352, "height": 35, "left": 251}, "words": "04mL/min。尚未进行腹膜透析清除阿德韦的研究"}, {"probability": {"variance": 4.7e-05, "average": 0.995595, "min": 0.981997}, "location": {"width": 120, "top": 388, "height": 32, "left": 250}, "words": "【药理理】"}, {"probability": {"variance": 0.001808, "average": 0.969628, "min": 0.909489}, "location": {"width": 88, "top": 430, "height": 26, "left": 245}, "words": "药理作"}, {"probability": {"variance": 0.016517, "average": 0.928543, "min": 0.396279}, "location": {"width": 794, "top": 471, "height": 42, "left": 285}, "words": "作用机制:本品阿德福带酯是一种口服抗病毒药阿可得福韦酯在体内代谢成阿福韦"}, {"probability": {"variance": 0.002367, "average": 0.973975, "min": 0.77055}, "location": {"width": 852, "top": 508, "height": 44, "left": 240}, "words": "阿德福韦是一种单磷酸腺苷的无环核苷类似物,在细胞激酶的作用下进一步被磷酸化为有活"}, {"probability": {"variance": 0.017983, "average": 0.958693, "min": 0.350671}, "location": {"width": 852, "top": 546, "height": 45, "left": 239}, "words": "性的代谢产物即阿德福韦二磷酸盐阿德福韦二磷酸盐通过下列二种方式来抑制 HBV DNA"}, {"probability": {"variance": 0.012348, "average": 0.958436, "min": 0.41006}, "location": {"width": 845, "top": 585, "height": 46, "left": 240}, "words": "多聚酶(转录酶):一是与自然底物脱氧腺苷三磷酸竞争二是整合到病毒DNA后引起DNA"}, {"probability": {"variance": 0.022417, "average": 0.919636, "min": 0.419767}, "location": {"width": 850, "top": 624, "height": 46, "left": 239}, "words": "链延长终止阿德福磷酸盐对 HBV DNA聚酶的抑制常数(Ki)是01μM,但对人"}, {"probability": {"variance": 0.022529, "average": 0.890066, "min": 0.378406}, "location": {"width": 675, "top": 663, "height": 42, "left": 235}, "words": "类NA聚酶a和的抑制作用较弱Ki值分别:18M和0:97M"}, {"probability": {"variance": 0.018534, "average": 0.912532, "min": 0.370853}, "location": {"width": 812, "top": 702, "height": 46, "left": 278}, "words": "抗病毒活性在转染HBM的火肝瘤细胞系中,阿德福抑制50%病毒DNA复制的浓度"}, {"probability": {"variance": 0.041116, "average": 0.809628, "min": 0.377915}, "location": {"width": 194, "top": 743, "height": 28, "left": 233}, "words": "(C50)为02~25:M"}, {"probability": {"variance": 0.018258, "average": 0.925559, "min": 0.466629}, "location": {"width": 810, "top": 780, "height": 45, "left": 276}, "words": "耐药性对接受阿德痛丰酯治疗奶然可检液到血消 BV DNA的患者进行了长期耐药性"}, {"probability": {"variance": 0.031211, "average": 0.878697, "min": 0.365995}, "location": {"width": 857, "top": 818, "height": 46, "left": 233}, "words": "分(96144周),确定了N236T和rA181V异与阿德福韦耐药有关;体外研究发现"}, {"probability": {"variance": 0.031451, "average": 0.87608, "min": 0.390132}, "location": {"width": 857, "top": 857, "height": 47, "left": 232}, "words": "rN236T交异导致B对阿微福市的敏感性降低14倍.产生这种变开的66名者的"}, {"probability": {"variance": 0.038767, "average": 0.813096, "min": 0.390656}, "location": {"width": 708, "top": 894, "height": 48, "left": 232}, "words": "血清 BV EMA发生茂跳A8Y变异导致上B对阿福市的敏感强"}, {"probability": {"variance": 0.038687, "average": 0.828824, "min": 0.415068}, "location": {"width": 804, "top": 933, "height": 49, "left": 228}, "words": "这种变异的2患者发生反跳。与阿德福专耐经关的变异发生率04周为00"}, {"probability": {"variance": 0.011957, "average": 0.921287, "min": 0.650754}, "location": {"width": 357, "top": 974, "height": 38, "left": 230}, "words": "49~96周为2%(6地93),97144周为"}, {"probability": {"variance": 0.029256, "average": 0.912205, "min": 0.533055}, "location": {"width": 262, "top": 986, "height": 31, "left": 671}, "words": "3),3年的累计发生为"}, {"probability": {"variance": 0.027495, "average": 0.889679, "min": 0.381958}, "location": {"width": 769, "top": 1011, "height": 52, "left": 269}, "words": "交叉耐药性=在 HBV DNA多聚酶基因上含对拉米定耐药相关突变nE180M,"}, {"probability": {"variance": 0.026324, "average": 0.857257, "min": 0.414668}, "location": {"width": 859, "top": 1053, "height": 47, "left": 225}, "words": "tM204V,r180MrtM120mV,VV3L)的重组HBV变异株,在体外对阿德丰敏在含"}, {"probability": {"variance": 0.043089, "average": 0.849972, "min": 0.411656}, "location": {"width": 865, "top": 1089, "height": 52, "left": 223}, "words": "拉米大定附药关变异的患者中阿德福韦酯也显示抗HBV作用,其血清 HBV DNA"}, {"probability": {"variance": 0.035926, "average": 0.862814, "min": 0.359713}, "location": {"width": 859, "top": 1127, "height": 50, "left": 225}, "words": "下降的中位数为4.3I0gO贝数/毫升。含DN多聚酶突变(rtT28N和 RRIS3Q或rtW53Q,与"}, {"probability": {"variance": 0.01389, "average": 0.944254, "min": 0.471238}, "location": {"width": 864, "top": 1164, "height": 52, "left": 221}, "words": "乙型肝炎免疫球蛋白耐药相关)的HBV变异株,在体外对阿德福韦敏感。体外研究显示,表"}, {"probability": {"variance": 0.020803, "average": 0.933281, "min": 0.363581}, "location": {"width": 865, "top": 1204, "height": 51, "left": 219}, "words": "达与德福韦耐药相关的tN236T突变的HBV对拉米夫定的敏感性降低23倍,而与阿德福"}, {"probability": {"variance": 0.005162, "average": 0.970436, "min": 0.63873}, "location": {"width": 597, "top": 1242, "height": 45, "left": 219}, "words": "韦耐药相关的A181V突变的HB对拉米夫定的敏感性降低3倍"}, {"probability": {"variance": 4.3e-05, "average": 0.995418, "min": 0.984136}, "location": {"width": 88, "top": 1286, "height": 24, "left": 219}, "words": "毒理研究"}, {"probability": {"variance": 0.006427, "average": 0.974437, "min": 0.517597}, "location": {"width": 821, "top": 1324, "height": 45, "left": 261}, "words": "慢性毒性:在动物试验中,以组织学改变和/或尿素氮及血清肌酐升高为特征的肾小管"}, {"probability": {"variance": 0.00116, "average": 0.986844, "min": 0.814821}, "location": {"width": 866, "top": 1361, "height": 47, "left": 214}, "words": "肾病,是阿德福韦酯的主要剂量限制性毒性反应。在动物试验中观察到的肾毒性发生的暴露"}, {"probability": {"variance": 0.000603, "average": 0.986976, "min": 0.881163}, "location": {"width": 442, "top": 1398, "height": 41, "left": 214}, "words": "量约为推荐的人治疗量10mg天)下的3~10倍"}, {"probability": {"variance": 0.012523, "average": 0.951136, "min": 0.366329}, "location": {"width": 821, "top": 1434, "height": 48, "left": 258}, "words": "遗传毒性;阿德福韦在加和不加代谢活化统(S9)的条件下、对鼠伤寒沙门氏菌"}, {"probability": {"variance": 0.009384, "average": 0.967052, "min": 0.467933}, "location": {"width": 867, "top": 1466, "height": 50, "left": 212}, "words": "均无致突变性。阿德福韦配对中国仓鼠肺成纤维细胞(CHL)体外染色体在加入代谢活化系"}, {"probability": {"variance": 0.006917, "average": 0.975903, "min": 0.606169}, "location": {"width": 868, "top": 1501, "height": 49, "left": 211}, "words": "统后,无明显致染色体畸变的作用。阿德福韦酯对ICR小鼠微核试验结果为阴性,阿德福"}, {"probability": {"variance": 6.1e-05, "average": 0.994378, "min": 0.965772}, "location": {"width": 442, "top": 1535, "height": 39, "left": 211}, "words": "韦在有或无代谢活化时Ames试验结果为阴性"}], "language": 3}